Marijuana has the ability to improve daily life for millions of people across the globe and for this reason, we believe that biotech companies focused on this opportunity will be one of the biggest winners.
Earlier this month, we highlighted Tetra Bio-Pharma Inc. (TBP.CN) (TBPMF) as an opportunity that has flown under the radar and believe this is a stock investors need to watch as it continues to work to create enormous value for its shareholders.
Tetra Bio-Pharma is trending higher after the company announced that it would commence trading on the TSX Venture exchange and voluntarily de-list from the Canadian Securities Exchange.
A Company that Continues to Execute
The last few months have been busy for Tetra and we expect these developments to play a significant role in the company’s success.
Tetra released a corporate update last month and highlighted some of potential catalysts for the company. Some of the potential catalysts include:
• In the fourth quarter, the company will start preparing for Phase III clinical trials of PPP001 with approx. 600 subjects
• Tetra is looking at new international markets and is focused on expanding commercialization partnerships for its product pipeline. The company has received interest from the United States, Germany, Ireland, Brazil and Mexico
• Tetra will soon launch its PPP001 product using the ACMPR license
• Will commence Phase II clinical trials for PPP002 – Dronabinol XL
Working to Bring Patented Products to Canada
Last month, Tetra signed a letter of intent with San Francisco-based Constance Therapeutics for the clinical development and commercialization of its patent-pending medicinal cannabis extract products in Canada.
Constance Therapeutics works in conjunction with physicians and medical professionals to provide integrative medicinal options to those suffering from serious conditions. Tetra’s AgroTek Health subsidiary will work with Constance to bring these products to the Canadian medical marijuana market under a commercial license agreement.
Tetra will enter a licensing agreement with Constance to perform clinical research on the novel cannabis extract products. These products are currently available to patients living in California and are consumed sublingually and through vaporization.
Too Many Catalysts to Ignore
With several significant catalysts on the horizon, investors need to be keeping an eye on Tetra Bio-Pharma. The shares have been trending higher after it started trading on the TSX Venture Exchange and we continue to see more upside from these levels.
If Tetra executes on its strategy, we expect to see significant top-line growth. The company is well capitalized and will not need to raise capital to complete clinical trials.
The combination of these catalysts, its strategic partners and its strong balance sheets, makes Tetra Bio-Pharma a company that cannot be ignored.
MAPH Enterprises LLC, owners of MarijuanaStocks.com, has been compensated $75,000 cash and 250,000 restricted shares by Tetra Bio-Pharma Inc. (TBP.CN) (TBPMF) for a period beginning May 8th, 2017 and ending August 31st, 2017 to publicly disseminate information about Tetra Bio-Pharma Inc. (TBP.CN) (TBPMF)
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
